Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
89 hedge funds and large institutions have $133M invested in Concert Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 23 reducing their positions, and 17 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 23
1% more capital invested
Capital invested by funds: $132M → $133M (+$1.04M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 94 → 89 (-5)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.92M |
| 2 |
ISL
Ingalls & Snyder LLC
New York
|
+$1.59M |
| 3 |
Millennium Management
New York
|
+$1.06M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.04M |
| 5 |
Renaissance Technologies
New York
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.19M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.95M |
| 3 |
SIM
Spark Investment Management
New York
|
-$1.81M |
| 4 |
SAM
Senzar Asset Management
New York
|
-$1.57M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$1.5M |
CNCE Hedge Fund Activity: Q4 2016 in Review
89 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q4 2016, worth a combined $133M — up 0.79% from $132M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CNCE and 14 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 33 added.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $4.92M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $4.19M sold.
- 89 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q4 2016, down from 94 in Q3 2016.
- Funds reported $133M of Concert Pharmaceuticals, Inc. stock for Q4 2016, up 0.79% quarter-over-quarter.
- 14 funds opened new Concert Pharmaceuticals, Inc. positions in Q4 2016 and 17 closed out, a net change of -3 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q4 2016 was Cormorant Asset Management, an estimated $4.92M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q4 2016 was Point72 Asset Management, an estimated $4.19M sold.
Based on aggregated 13F filings for Q4 2016.